Drug Trial Radar · NCT07015762
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jul 14, 2025
Primary completion
May 20, 2026
Study completion May 20, 2026
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of IBI3002 in participants with moderate to severe atopic dermatitis (AD). The study plans to enroll patients with moderate to severe AD who have a poor response to topical treatment or who are not suitable for topical treatments. It aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, PD characteristics, and changes in clinical characteristics of these participants receiving multiple doses of IBI3002. The entire study includes the screening period (4 weeks before dosing), the dosing period (12 weeks), and the safety follow-up period (8 weeks). The study plans to enroll 9 to 27 participants with moderate to severe AD, who will be randomly assigned in a 1:1:1 ratio to the following 3 cohorts to receive subcutaneous injection of the corresponding dose of IBI3002 or a matching volume of placebo. Investigators and participants remain blind within the same cohort. Cohort 1: 150mg SC (IBI3002: placebo=2 :1); Cohort 2: 300mg SC (IBI3002: placebo=2 :1); Cohort 3: 600mg SC( IBI3002: placebo=2 :1); The participants need to be observed at the study site for 3 hours after each dose and are allowed to leave after investigators determine no safety risk.
Conditions
- Atopic Dermatitis
Interventions
IBI3002Drug
Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.
PlaceboDrug
Participants with AD will receive placebo at the corresponding volume and dosing interval.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of multiple doses of IBI3002 in Atopic Dermatitis patients.Time frame: Baseline to Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.